Breast Positioning Articles & Analysis
5 articles found
Two are for HER2 breast cancer ADCs. T-DM1(Ado-trastuzumab Emtansine) T-DM1 is the first ADC drug to target HER2-positive breast cancer. ...
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by AstraZeneca and Daiichi Sankyo, for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 drugs. ...
Worldwide, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in women, with over 650,000 deaths in 2020.1,2 Human epidermal growth factor receptor 2 (HER2)-targeted agents have improved outcomes in HER2-positive breast cancer, but most patients in first-line therapy do not respond to current therapies, ...
The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in 2013 for treatment in HER2-positive breast cancer patients. This novel ADC is very effective in HER2-positive breast cancer ...
Traditional small molecule-based ADCs are showing meaningful advantages in difficult-to-treat indications such as triple-negative breast cancer, and new drug design paradigms are emerging, such as new payload classes including oligonucleotides, proteins, and degradates. ...